Dosage and administration of Risankizumab

Risankizumab/Risankizumab (Risankizumab) has clear dosage and administration methods in the treatment of various immune-mediated diseases. A thorough evaluation of the patient is very important before applying this drug, especially in the treatment of psoriasis, psoriatic arthritis (PA), ulcerative colitis, Crohn's disease (CD). Doctors need to obtain the patient's liver enzyme and bilirubin levels and evaluate for tuberculosis (TB) infection. Additionally, patients should be ensured that they have completed all age-appropriate vaccinations according to current immunization guidelines.

For different diseases, the recommended dosage and usage of risancizumab are as follows:

1. Plaque psoriasis: For patients with moderate to severe plaque psoriasis, it is recommended to use 150mg dose by subcutaneous injection. Initial injections are given at weeks 0 and 4, followed by injections every 12 weeks thereafter.

2. Psoriatic arthritis: The same dosage of 150 mg is also suitable for patients with psoriatic arthritis. The dosage regimen is similar to that of plaque psoriasis. You can choose to give it alone or in combination with non-biological antirheumatic drugs (DMARDs) to improve the efficacy.

3. Crohn's disease: For adult patients with Crohn's disease, the induction dose is600mg, administered by intravenous infusion in three divided doses at weeks 0, 4 and 8, with each infusion lasting at least 1 hour. The maintenance dose is 180 mg or 360 mg, administered by subcutaneous injection at week 12 and every 8 weeks thereafter to ensure the lowest effective dose required to maintain a therapeutic response.

4. Ulcerative colitis: The induction dose for adult patients with ulcerative colitis is 1200mg, which is also infused intravenously in three doses at weeks 0, 4 and 8. The infusion time is no less than 2 hours. The maintenance dose is 180 mg or 360 mg by subcutaneous injection at week 12 and then every 8 weeks to maintain therapeutic effect.

In summary, the use of risantekizumab needs to follow specific dosage and administration methods, and necessary health assessments should be conducted before use to ensure patient safety and optimal therapeutic effects.

Reference materials:https://go.drugbank.com/drugs/DB14762